1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

30 Aug 2024
Admin
News Article

Chugai Pharmaceutical Announces Approval of Alecensa® in Japan

Overview

Chugai Pharmaceutical has secured approval for an additional indication of Alecensa® (alectinib), its ALK inhibitor and antineoplastic agent, for use as adjuvant therapy in ALK fusion gene-positive non-small cell lung cancer (NSCLC).

Phase III Clinical Trial

This approval is grounded in findings from the ALINA study, the first global Phase III clinical trial focused on early-stage ALK-positive resected NSCLC.
The study demonstrated that Alecensa reduced the risk of disease recurrence or death by 76%, marking a significant advancement in the treatment of this condition.

Addressing Unmet Need

This approval addresses a critical unmet need, as approximately half of individuals with early-stage NSCLC experience disease recurrence after surgery, despite undergoing adjuvant chemotherapy.
In Japan, the new indication is expected to significantly reduce the risk of postoperative recurrence, offering hope for a complete cure and long-term survival for patients with ALK-positive NSCLC, thereby improving their quality of life.

About ALINA Study

The ALINA study, a Phase III randomized, active-controlled, multicenter, open-label trial, evaluated the efficacy and safety of adjuvant Alecensa compared to platinum-based chemotherapy in patients with resected Stage IB (tumors ≥ 4 cm) to IIIA ALK-positive NSCLC.
The trial involved 257 patients, randomly assigned to either the Alecensa or chemotherapy treatment arms.
Alecensa showed a 76% reduction in the risk of disease recurrence or death (hazard ratio [HR]=0.24, 95% CI: 0.13-0.43, p<0.0001) compared to platinum-based chemotherapy.
The safety and tolerability profile of Alecensa in the ALINA trial was consistent with previous studies conducted in the metastatic setting, with no unexpected safety concerns.

About Lung Cancer

Lung cancer remains one of the leading causes of cancer-related deaths globally, with 1.8 million fatalities annually.
In Japan, lung cancer affected 127,000 individuals in 2019.
Non-small cell lung cancer (NSCLC) is the most common type, comprising approximately 85% of all lung cancer cases.
Despite advances in treatment, 45-76% of patients with early-stage lung cancer still experience recurrence after surgery, underscoring the importance of early treatment to prevent disease return and improve chances of a cure

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!